Introduction {#S0001}
============

Long noncoding RNAs (lncRNAs) represent a large family of RNAs without protein-coding capability that are characterized by a length of more than 200 nucleotides and the lack of an identifiable open reading frame (ORF).[@CIT0001]--[@CIT0006] As revealed by the research to date, upregulation of some lncRNAs is evident in several cancer tissues and cell lines, in comparison to the tissues surrounding the cancer and normal cell lines, respectively. Additionally, some of these lncRNAs have pro-oncogenic potential; conversely, some others are reported to have low expression levels and tumour-suppressive functions.[@CIT0007]--[@CIT0010]

Among the lncRNAs, the small nucleolar RNA host gene 1 (*SNHG1*; also known as *UHG*, *U22HG*, *lncRNA16*, *LINC00057*, and *NCRNA00057*) has garnered our attention. Specification of *SNHG1* mechanisms extends our understanding of invasive pathophysiology. Additionally, overexpression of *SNHG1* is reported to be a predictor of oncogenesis in patients with many kinds of cancer, including oesophageal squamous cell carcinoma,[@CIT0011] lung squamous cell carcinoma,[@CIT0012] hepatocellular carcinoma,[@CIT0013],[@CIT0014] colorectal cancer[@CIT0015],[@CIT0016] and gastric cancer.[@CIT0017]

As revealed by the growing number of research studies, *SNHG1* is likely to perform the function of a diagnostic and a prognostic biomarker with regard to the cancers stated above. For the purpose of validating its clinical relevance as a biomarker or therapeutic target, it was deemed quite necessary to investigate whether *SNHG1* expression level is associated with pathological features. The current research study is aimed at carrying out a meta-analysis of this association in human cancers.

Materials and methods {#S0002}
=====================

Literature search strategies {#S0002-S2001}
----------------------------

Independent identification of the relevant literature was performed by two scholars with the use of both PubMed and Web of Science. The relevant literature reported the connection between *SNHG1* expression level and pathological attributes in human cancers. The literature search strategy included a combination of keywords ("*SNHG1*", "*LINC00057*", "*lncRNA16*", "cancer or carcinoma or tumour or neoplasm", and "pathology"). In addition, the references of attained literature were also examined for the identification of additional relevant studies.

Inclusion and exclusion criteria {#S0002-S2002}
--------------------------------

The research studies involved in this analysis were required to satisfy the inclusion criteria listed here: 1) reported expression levels of *SNHG1*, as determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR); 2) put forward the decision; 3) segregated the patients into high and low expression groups with the help of definite criteria for *SNHG1* expression levels; 4) reported data associated with the clinicopathological attributes of the patients, and at a minimum, one of the following pathological features: TNM stage, histological grade, lymph node metastasis, distant metastasis, and overall survival information; and 5) utilized a case-control or cohort study design.

Research studies were not included in the analysis if they met any of the exclusion criteria listed here: 1) stated recurring research reports or studies that included patients who were reported in a former research study; 2) provided insufficient statements of the data; 3) employed nonhuman specimens; 4) were reviews, together with letters, unpublished data, and commentaries; and 5) were reports that were not published in the English language.

Assessment of the quality of the research studies was performed by two scholars by going through the title, abstract, and complete text of each report while referencing the inclusion and exclusion criteria.

Literature screening and data extraction {#S0002-S2003}
----------------------------------------

Independent collection of the data was performed by two investigators (Yang Yu and Jian Yang), in accordance with both the inclusion and exclusion criteria, and after resolving any conflicts with the help of a consensus or talks with a third scholar (Shengquan Yang) prior to the performance of the analysis. Data extraction from the literature included the following: first author, publication year, country of data source, kind of cancer, number of patients placed in both the high and low *SNHG1* expression cohorts, the *SNHG1* expression level identification methodology, and the cut-off approximations for *SNHG1* expression levels.

Quality assessment {#S0002-S2004}
------------------

Assessment of the quality of the involved research studies was performed with the help of the Newcastle-Ottawa Scale standard that assessed selection (four points), comparability (two points), and outcome (three points) and had a score ranging between 0 and 9. Each of the qualifying studies was scored in [Table 1](#T0001){ref-type="table"}, with a higher score suggesting better methodological quality.Table 1Characteristics of the included studiesAuthor name (year)CountryCancer typeTotal numberHighLowCutoff (high/low)Detection methodQuality scoreJiandong Wang (2017 May)ChinaOsteosarcoma442717MeanqRT-PCR7Hong-Yan Zhang (2017 March)ChinaLung squamous cell carcinoma623626MeanqRT-PCR6Hui Zhang (2016 December)ChinaHepatocellular carcinoma1227052MeanqRT-PCR6Min Zhang (2016 February)ChinaHepatocellular carcinoma824141MedianqRT-PCR6Tian Tian (2017 December)ChinaColorectal cancer824141MedianqRT-PCR8Yijun Zhang (2017 December)ChinaEsophageal squamous cell carcinoma723834MeanqRT-PCR6Yongbo Hu (2017 July)ChinaGastric cancer50------qRT-PCR6Yun Cui (2017 January)ChinaNon-small cell lung cancer683434MedianqRT-PCR8Yuping Zhu (2017 December)ChinaColorectal cancer1085454MedianqRT-PCR8Zhe Jiang (2017 November)ChinaOsteosarcoma25196MeanqRT-PCR6[^2]

Statistical analysis {#S0002-S2005}
--------------------

Cochran's Q and Chi-square-based I^2^ tests were used for the determination of the heterogeneity among the involved research studies. Homogeneity tests were carried out using a significance level of α =0.1. *P*-values \<0.1 were regarded as being statistically significant, whereas I^2^ values \>50% implied heterogeneity among the research studies. Analysis of the homogeneous data was carried out with the use of a fixed effects framework; otherwise, a random effects framework was used for the analysis. Statistical analyses, together with the assessment of publication bias and Begg's methodology, was carried out using StataSE 12.0 (Stata Corp LP, College Station, Texas, USA).

Results {#S0003}
=======

Data selection and characteristics {#S0003-S2001}
----------------------------------

Ten research studies that involved an aggregate of 715 patients showed agreement with the inclusion criteria. Each and every research study originated from China; two were studies of colorectal cancer, two were studies of hepatocellular carcinoma, two were studies of lung cancer, two were studies of osteosarcoma, and the remaining two were studies of oesophageal squamous cell carcinoma and gastric cancer. QRT-PCR was used for detecting *SNHG1*, on the basis of which, categorization of the patients into groups of high and low *SNHG1* expression was performed. The mean and median were employed as the cut-off values for estimating for the *SNHG1* expression level. A summary of the attributes of the involved research studies is provided in [Table 1](#T0001){ref-type="table"}, whereas the flowchart of the study search, together with the selection process, is presented in [Figure 1](#F0001){ref-type="fig"}.Figure 1Flowchart of selecting studies for inclusion.

Association between SNHG1 expression and pathological features {#S0003-S2002}
--------------------------------------------------------------

### TNM stage {#S0003-S2002-S3001}

Eight research studies reported a link between *SNHG1* expression and TNM stage (III/IV versus I/II). There was no statistically significant (*P*\>0.05, *I*^2^=0.00%) heterogeneity among the research studies; accordingly, the fixed-effects framework was applied for the calculation of the accumulated pooled RR, together with its 95% CI, which reached statistical significance \[RR =1.88, 95% CI (1.58, 2.24), *P*\<0.001\] ([Figure 2](#F0002){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). This suggests that a high *SNHG1* expression level has a link with advanced TNM phase.Table 2Meta analysis results for the association of over-expressed *SNHG1* with clinicopathological parametersClinicopathological parametersStudies (n)Number of patientsRR (95% CI)*P*-valueHeterogeneity*I*^2^P~h~ModelTNM stage (III/IV vs I/II)86211.879 (1.579, 2.237)0.0000.00%0.790Fixed effectsHistological grade (poorly/others vs well/moderately)43301.384 (1.090, 1.757)0.0080.00%0.507Fixed effectsLymph node metastasis (+ vs --)53351.799 (1.416, 2.285)0.0000.00%0.702Fixed effectsDistant metastasis (+ vs --)33121.288 (0.798, 2.079)0.30040.6%0.186Fixed effects Figure 2Forest plot for the association between *SNHG1* expression and TNM stage in human cancers.

### Histological grade {#S0003-S2002-S3002}

Reports from an aggregate of 4 research studies revealed the association between *SNHG1* expression and histological grade. Statistically significant (*P*\>0.05, *I*^2^=0.00%) heterogeneity among the research studies was not observed; accordingly, the fixed-effects framework was applied for the calculation of the accumulated RR, together with its 95% CI, which exhibited a statistically significant difference \[RR =1.38, 95% CI (1.09, 1.76), *P*\<0.01\] ([Figure 3](#F0003){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). This suggested that high *SNHG1* expression was associated with a higher risk of poorly differentiated histological grade.Figure 3Forest plot for the association between *SNHG1* expression and histological grade in human cancers.

### Lymph node metastasis {#S0003-S2002-S3003}

Reports from an aggregate of 5 research studies suggested a connection between *SNHG1* expression and lymph node metastasis. Statistically significant (*P*\>0.05, *I*=0.00%) heterogeneity was not observed among the studies; accordingly, the fixed-effects framework was applied for the calculation of the accumulated RR, together with its 95% CI, which reached statistical significance \[RR =1.8, 95% CI (1.42, 2.29), *P*\<0.001\] ([Figure 4](#F0004){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). This association illustrates the fact that the cohort with the high *SNHG1* expression level exhibited a higher risk of lymph node metastasis compared with the cohort with the low *SNHG1* expression levels.Figure 4Forest plot for the association between *SNHG1* expression and lymph node metastasis in human cancers.

### Distant metastasis {#S0003-S2002-S3004}

Reports from 3 research studies revealed a link between *SNHG1* expression level and distant metastasis. Statistically significant (*P*\>0.05, *I*=0.00%) heterogeneity among the research studies was not observed; accordingly, the fixed-effects framework was applied for the calculation of the accumulated RR, together with its 95% CI, which did not reach statistical significance \[RR =1.29, 95% CI (0.80, 2.08), *P*\>0.05\] ([Figure 5](#F0005){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). This result highlights that *SNHG1* expression levels have no correlation with distant metastasis. The reasons behind the inexistence of any correlation could include that the number of patients registered in some of the research works was comparatively smaller; moreover, not every kind of cancer was studied, and no consensus on the cut-off for making a distinction between a high or low *SNHG1* expression level was observed. As such, future studies comprising larger samples of patients are going to be needed; moreover, the cut-off value for making a distinction between high or low *SNHG1* expression level requires consistency as well.Figure 5Forest plot for the association between *SNHG1* expression and distant metastasis in human cancers.

Association between SNHG1 expression and survival in different types of cancers {#S0004}
===============================================================================

In total, 5 research studies comprising 352 patients were employed for the assessment of the impact of *SNHG1* overexpression on OS in various cancers ([Table 3](#T0003){ref-type="table"}). Moreover, it was highlighted that augmented *SNHG1* expression forecasted a weak performance for OS in the involved cancer types \[pooled HR=3.36, 95% CI (2.42, 4.67), *P*\<0.001\], with heterogeneity (I^2^=57.3%, *P*\>0.05). In addition, a subgroup analysis was also performed on the basis of the aggregate number of each study concerned. A substantial connection between *SNHG1* overexpression and poor OS in the research studies with aggregate numbers below 80 patients was noted \[pooled HR =2.55, 95% CI (1.52, 4.26)) ([Figure 6](#F0006){ref-type="fig"}). In comparison with the low *SNHG1* expression cohort, the high *SNHG1* expression group exhibited a statistically significant decline in OS, in addition to being correlated with worse survival.Table 3Characteristics of the overall survival of the included studiesAuthor name (year)CountryCancer typeSurvival analysisHR statisticHR (95%CI)Follow-up monthsOutcomeJiandong Wang (2017 May)ChinaOsteosarcomaUnivariteSurvival curves1.41 (0.50, 4.00)60OSMin Zhang (2016 February)ChinaHepatocellular carcinomaUnivariteSurvival curves1.92 (0.86, 4.35)60OSYongbo Hu (2017 July)ChinaGastric cancerUnivariteSurvival curves3.92 (1.91, 8.06)60OSYun Cui (2017 January)ChinaNon-small cell lung cancerUnivariteSurvival curves1.89 (0.79, 6.25)60OSYuping Zhu (2017 December)ChinaColorectal cancerUnivariteData in paper5.41 (2.47, 6.71)60OS[^3] Figure 6Meta-analysis for the pooled HRs of overall survival in patients with various cancers.

Assessment of publication bias {#S0004-S2001}
------------------------------

Due to the small number of research studies included, analysis of publication bias was not possible for TNM phase, histological grade, lymph node metastasis, or distant metastasis.

Discussion {#S0005}
==========

To date, deregulation of lncRNAs has been observed in numerous human cancers. Additionally, deregulation of lncRNAs has been linked to cancer proliferation by acting as a regulator in alternative splicing and translation, by promoting steadiness of the host mRNAs with the help of post-transcriptional phenomena, or by acting as the scaffolding or instructions for regulating protein-protein or protein-DNA interactions.[@CIT0018],[@CIT0019]

The current meta-analysis was aimed at investigating the link between *SNHG1* expression levels and pathological attributes observed in human cancers. In total, 715 patients from 10 research studies were eventually included. The fixed-effects framework was applied for the assessment of TNM stage and histological grade, lymph node metastasis, and distant metastasis. Consequently, the cohort with the high *SNHG1* expression level exhibited a higher risk of advanced TNM stage, poorly differentiated grade and lymph node metastasis compared to the low *SNHG1* expression level group. In addition, in regard to prognosis, the patients with high expression of *SNHG1* experienced relatively short overall survival.

Nonetheless, this research study has some limitations: (1) each and every involved research study originated from China and no patients from any other country were included; (2) the number of patients registered in some of the research studies was comparatively smaller and not all the cancer types were studied; (3) no consensus was reached regarding the cut-off level for making a distinction between a high or low *SNHG1* expression level; (4) no cohort studies observed met the inclusion criteria. High-quality studies with large sample sizes are necessary for the confirmation of these results.

To summarize, with regard to the clinicopathology, high expression levels of *SNHG1* had a close association with advanced TNM stage, poorly differentiated grade, and lymph node metastasis. In addition, with regards to prognosis, the patients having a high expression level of *SNHG1* experienced relatively poor overall survival (OS). Notably, *SNHG1* is capable of acting as a biomarker of poor prognosis for patients with cancer.

Conclusion {#S0006}
==========

This meta-analysis discovered that augmented *SNHG1* expression is common in a number of different kinds of cancer and has a likelihood of acting as an innovative predictive element of poor prognosis and lymph node metastasis in various cancers. Nonetheless, it is still deemed essential to carry out research studies with a larger sample size, and with an improved design, for the confirmation of our findings.
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